SOTIO® Biotech is developing the next generation of potent immunotherapies for patients with cancer.

 

Join Our Team

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. We are looking for talented, motivated, dynamic employees to join our international ...

Business Development

SOTIO aims to become a diverse oncology company that develops early stage candidates into marketed immunotherapy products. We seek to add to our portfolio projects that are at advanced preclinical or clinical stages.

NEWS

SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline; SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF ...

SOTIO Programs

Immunocytokines

SOTIO’s immunocytokine platform is designed to preferentially activate immune cells in the tumor microenvironment by targeted delivery of a cytokine agonist.   

BOXR

SOTIO’s BOXR cell therapy platform is designed to improve the functionality of engineered T cells by identifying novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment. 

Antibody-Drug Conjugates

SOTIO’s proprietary antibody-drug conjugate (ADC) platform yields potent and highly stable ADCs with a wide therapeutic window for the treatment of cancer …

Contacts

Boston
Boston
SOTIO Biotech Inc.
180 Canal St,
Suite 300
Boston, MA 02114
USA
CONTACT
Prague
Prague
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
CONTACT
Basel
Basel
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
CONTACT
Amsterdam
Amsterdam
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
CONTACT